SPINRAZA may offer improvements for important motor milestones
Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
Over 8 years
The safety profile of SPINRAZA has more than 8 years of follow-up data that is consistent with those previously reported.
3x/year
SPINRAZA is delivered directly to the central nervous system (CNS) where motor neuron loss begins. After 4 initial loading doses, SPINRAZA is given 3 times a year.
Extensive real-world experience across a broad range of ages†
†Based on commercial patients, early access patients, and clinical trial participants through September 2023.
‡SPINRAZA pivotal studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.